ChromaDex Corporation's Upcoming Financial Results
ChromaDex Corp. (NASDAQ: CDXC), a leader in nicotinamide adenine dinucleotide (NAD+) research focused on promoting healthy aging, is gearing up to report its financial results for the third quarter of 2024. The report is set to be released following the close of the market on Thursday, October 31, 2024. This announcement is part of the company’s commitment to transparency and engagement with its investors.
Conference Call Scheduled for Updates
In conjunction with the financial results, ChromaDex management has scheduled a conference call for Wednesday, November 6, 2024, at 4:30 p.m. ET. During this call, the leadership team will discuss the quarterly outcomes and provide insights into ongoing business developments. Participation is encouraged, and attendees are advised to join the call at least ten minutes early to ensure a smooth experience.
Important Details for Participants
Participants in the conference call can use the following information:
Date: Wednesday, November 6, 2024
Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: 1-888-596-4144
Conference ID: 8584242
Live Broadcast and Replay Options
The call will be broadcast live for public access, and those who cannot attend the live session will have the option to listen to the replay later. The replay of the conference call will be available from 7:30 p.m. EDT on November 6, 2024, to 11:59 p.m. EDT on Wednesday, November 13, 2024. The toll-free number for the replay is 1-800-770-2030, using Replay ID: 8584242#.
Company Overview: ChromaDex's Mission
ChromaDex Corp. (NASDAQ: CDXC) has established itself as a prominent authority in NAD+ research, a crucial component related to aging and overall wellness. The findings from their research arm have drawn attention for their contributions to understanding better ways to maintain vitality as people age. The company employs a team of renowned scientists who collaborate with prestigious universities and research institutions globally, exploring the potential of NAD+.
Niagen: The Innovative Ingredient
ChromaDex is known for its patented ingredient, Niagen, which is scientifically recognized as a superior NAD+ booster. This ingredient is available in its flagship product, Tru Niagen®, widely regarded as the leading NAD+ supplement in the United States. Niagen is essential for cellular functions and tends to decline with age, making it vital for enhancing overall well-being.
FDA Registered Products
The company ensures that Niagen® meets stringent quality and safety benchmarks by supplying pharmaceutical-grade formulations specifically for clinics that offer intravenous and injectable solutions. These products are intended for patients under medical supervision and are only available through prescription.
Advancements in Healthy Aging
As ChromaDex continues to innovate within the realm of healthy aging, their commitment to exploring the complexities of NAD+ remains a principal focus. Their extensive patent portfolio underlines their dedication to protecting their discoveries and developments in this field. For more information on the latest advancements, including research and product releases, the company regularly updates its stakeholder materials through its primary website.
Frequently Asked Questions
What are the financial results ChromaDex will report?
ChromaDex will detail its third quarter 2024 financial performance, alongside a business update in the upcoming conference call.
When will the earnings conference call occur?
The earnings conference call is scheduled for November 6, 2024, at 4:30 p.m. ET.
How can I attend the ChromaDex conference call?
Participants can join via the toll-free number provided and should log in at least ten minutes before the start.
Is there a replay available for the conference call?
Yes, the call will be available for replay from November 6, 2024, at 7:30 p.m. EDT until November 13, 2024.
What products does ChromaDex offer?
ChromaDex offers Niagen®, a clinically proven supplement for boosting NAD+ levels, among other nutraceuticals aimed at promoting healthy aging.
